http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-035543-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5b65747ed78f05dd9ebe107b50ce2855 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D235-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D235-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4523 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D419-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2059 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4523 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D235-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D235-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D419-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 |
| filingDate | 2002-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8abba5cb7704e735d6e2aeb3b0c8309 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f56d592ce5810cb05eb5a64d5737471c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef4cf9e1b855a9fceb8724a64a68b89f |
| publicationDate | 2004-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-035543-A1 |
| titleOfInvention | THERAPEUTIC AGENT FOR HEPATITIS C THAT INCLUDES A CONDENSED RING COMPOUND, CONDENSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS, BENZIMIDAZOL, THIAZOL AND BIFENYL COMPOUNDS USED AS INTERMEDIARY COMPARTMENTS OF COMPARTMENTS |
| abstract | Therapeutic agent for hepatitis C comprising a condensed ring compound of the formula [1] where a dotted line is a single bond or a double bond; G1 is C (-R1) or a nitrogen atom; G2 is C (-R2) or a nitrogen atom; G3 is C (-R3) or a nitrogen atom; G4 is C (-R4) or a nitrogen atom; G5, G6, G8 and G9 are each independently a carbon atom or a nitrogen atom; G7 is C (-R7), an oxygen atom, a sulfur atom, or a nitrogen atom optionally substituted by R8; where R1, R2, R3 and R4 are each independently (1) a hydrogen atom, (2) C1-6 alkanoyl, (3) carboxyl, (4) cyano, (5) nitro, (6) C1 alkyl -6 optionally substituted by 1 to 3 substituent (s) selected from the following group A, [group A: a halogen atom, a hydroxyl group, carboxyl, amino, C1-6 alkoxy, C1-6 alkoxy C1-6 alkoxy , C1-6 alkoxycarbonyl and C1-6 alkylamino], (7) -COORa1 where Ra1 is optionally substituted C1-6 alkyl (as defined above) or C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent ( s) selected from the following group B, [group B: a halogen atom, cyano, nitro, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkanoyl, - (CH2) r-COORb1, - ( CH2) r-CONRb1Rb2, - (CH2) r-NRb1Rb2, - (CH2) r-NRb1-CORb2, - (CH2) r-NHSO2Rb1, - (CH2) r-ORb1, - (CH2) r-SRb1, - ( CH2) r-SO2Rb1 and - (CH2) r-SO2NRb1Rb2, where Rb1 and Rb2 are each, independently, a hydrogen atom or C1-6 alkyl and r is 0 or an integer of 1 to 6], (8) -CONRa2Ra3 where Ra2 and Ra3 are each, independently, a hydrogen atom, C1-6 alkoxy or optionally substituted C1-6 alkyl (as defined above), (9) -C ( = NRa4) NH2 where Ra4 is a hydrogen atom or a hydroxyl group, (10) -NHRa5 where Ra5 is a hydrogen atom, C1-6 alkanoyl or C1-6 alkylsulfonyl, (11) -ORa6 where Ra6 is an atom of hydrogen or optionally substituted C1-6 alkyl (as defined above), (12) -SO2Ra7 where Ra7 is a hydroxyl, amino, C1-6 alkyl or C1-6 alkylamino group, or (13) -P (= O ) (ORa31) 2 where Ra31 is a hydrogen atom, optionally substituted C1-6 alkyl (as defined above) or C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent (s) selected from previous group B, and (14) heterocyclic group having 1 to 4 heteroatom (s) selected from an oxygen atom, a nitrogen atom and a sulfur atom; and R7 and R8 are each an optionally substituted hydrogen or C1-6 alkyl atom (as defined above); The Cy ring is (1) C3-8 cycloalkyl optionally substituted by 1 to 5 substituent (s) selected from the following group C, [group C: a hydroxyl group, a halogen atom, C1-6 alkyl and C1 alkoxy -6], (2) C3-8 cycloalkenyl optionally substituted by 1 to 5 substituent (s) selected from the above group C, or (3) a remainder of the formulas [2], [3], [4] or [5] where u and v are each, independently of each other, an integer from 1 to 3; Ring A is (1) C6-14 aryl, (2) C3-8 cycloalkyl, (3) C3-8 cycloalkenyl, or (4) a heterocyclic group having 1 to 4 heteroatom (s) selected from a oxygen, nitrogen and sulfur atom; R5 and R6 are each, independently, (1) a hydrogen atom, (2) a halogen atom, (3) optionally substituted C1-6 alkyl (as defined above), or (4) -ORa8 where Ra8 is a hydrogen atom, C1-6 alkyl or C6-14 aryl C1-6 alkyl; and X is (1) a hydrogen atom, (2) a halogen atom, (3) cyano, (4) nitro, (5) amino, C1-6 alkanoylamino, (6) C1-6 alkylsulfonyl, (7) optionally substituted C1-6 alkyl (as defined above), (8) C2-6 alkenyl optionally substituted by 1 to 3 substituent (s) selected from the above group A, (9) -COORa9 where Ra9 is a hydrogen atom or C1-6 alkyl, (10) -CONH- (CH2) l-Ra10 where Ra10 is optionally substituted C1-6 alkyl (as defined above), C1-6 alkoxycarbonyl or C1-6 alkanoylamino and l is 0 or an integer from 1 to 6, (11) -ORa11 where Ra11 is an optionally substituted hydrogen or C1-6 alkyl atom (as defined above), or (12) a compound of formula [6] where Ring B is (1 ') C6-14 aryl, (2') C3-8 cycloalkyl, or (3 ') a heterocyclic group (as defined above); each Z is, independently, (1 ') a group selected from the following group D, (2') C6-14 aryl optionally substituted by 1 to 5 substituent (s) selected from the following group D, (3 ') cycloalkyl C3-8 optionally substituted by 1 to 5 substituent (s) selected from the following group D, (4 ') aryl C6-14 C1-6 alkyl optionally substituted by 1 to 5 substituent (s) selected from the following group D, or (5 ') a heterocyclic group optionally substituted by 1 to 5 substituent (s) selected from the following group D, where the heterocyclic group has 1 to 4 heteroatom (s) selected from an oxygen atom , nitrogen and sulfur, (6 ') C1-6 alkyl heterocycle optionally substituted by 1 to 5 substituent (s) selected from the following group D, where the C1-6 alkyl heterocycle is C1-6 alkyl substituted by heterocycle group optionally substituted by 1 to 5 substituent (s) selected from group D; [as defined above, group D: (a) a hydrogen atom, (b) a halogen atom, (c) cyano, (d) nitro, (e) optionally substituted C1-6 alkyl (as is defined above), (f) - (CH2) t-CORa18 (hereafter, each t means independently, 0 or an integer from 1 to 6), where Ra18 is (1 '') C1-6 alkyl optionally substituted (as defined above), (2 '') C6-14 aryl optionally substituted by 1 to 5 substituent (s) selected from the previous group B or (3 '') a heterocyclic group optionally substituted by 1 a 5 substituent (s) selected from the previous group B where the heterocyclic group has 1 to 4 heteroatom (s) selected from an oxygen, nitrogen and sulfur atom, (g) - (CH2) t-COORa19 where Ra19 is a hydrogen atom, optionally substituted C1-6 alkyl (as defined above) or C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent (s) selected d the above group B, (h) - (CH2) t-CONRa27Ra28 where Ra27 and Ra28 are each independently (1 '') a hydrogen atom, (2 '') optionally substituted C1-6 alkyl (as is defined above), (3 '') C6-14 aryl optionally substituted by 1 to 5 substituent (s) selected from the previous group B, (4 '') C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent (s) selected from the previous group B, (5 '') a heterocyclic group optionally substituted by 1 to 5 substituent (s) selected from the previous group B, (6 '') C1- alkyl heterocycle 6 heterocyclic optionally substituted by 1 to 5 substituent (s) selected from the above group B, wherein the heterocyclic C1-6 alkyl heterocycle is C1-6 alkyl substituted by a heterocyclic group optionally substituted by 1 to 5 substituent (s) selected (s) of the above group B, as defined above, (7 '') C3-8 cycloalkyl optionally substituted by 1 to 5 substituent (s) s selected (s) from the previous group B, or (8 '') C3-8 cycloalkyl C1-6 alkyl optionally substituted by 1 to 5 substituent (s) selected from the previous group B, (9 '') hydroxyl group, or (10 '') C1-6 alkoxy, (i) - (CH2) tC (= NRa33) NH2 where Ra33 is a hydrogen atom or C1-6 alkyl, hydroxyl group or C1-6 alkoxy, (j) - (CH2 ) t-ORa20 where Ra20 is (1 '') a hydrogen atom, (2 '') optionally substituted C1-6 alkyl (as defined above), (3 '') optionally substituted C2-6 alkenyl (such as defined above), (4 '') C2-6 alkynyl optionally substituted by 1 to 3 substituent (s) selected from the above group A, (5 '') C6-14 aryl optionally substituted by 1 to 5 substituent (s) selected from the previous group B, (6 '') aryl C6-14 C1-6 alkyl optionally substituted by 1 to 5 substituent (s) selected from the previous group B, (7 '') a heterocyclic group optionally substituted by 1 to 5 substituent (s) selected from the previous group ior B, (8 '') heterocyclic C1-6 alkyl optionally substituted by 1 to 5 substituent (s) selected from the above group B, (9 '') C3-8 cycloalkyl optionally substituted by 1 to 5 substituent (s ) selected (s) from the previous group B, or (10 '') C3-8 cycloalkyl C1-6 alkyl optionally substituted by 1 to 5 substituent (s) selected from the previous group B, (k) - (CH2) tO - (CH2) p-CORa21 where Ra21 is amino, C1-6 alkylamino or a heterocyclic group optionally substituted by 1 to 5 substituents (s) selected from group B, and p is 0 or an integer from 1 to 6, (l) - (CH2) t-NRa22Ra23 where Ra22 and Ra23 are each independently (1 '') a hydrogen atom, (2 '') optionally substituted C1-6 alkyl (as defined above), (3 '') C6-14 aryl optionally substituted by 1 to 5 substituent (s) selected from the above group B, (4 '') C6-14 aryl C1-6 alkyl optionally substituted by 1 to 5 substituent (s) selected (s) from the previous group B, or (5 '') heterocyclic C1-6 alkyl optionally substituted by 1 to 5 substituent (s) selected from the above group B, (6 '') heterocyclic group optionally substituted by 1 to 5 selected substituent (s) from the previous group B, (m) - (CH2) t-Ra29CO-Ra24 where Ra29 is a hydrogen atom, C1-6 alkyl or C1-6 alkanoyl, and Ra24 is (1 '') amino, (2 '') C1-6 alkylamino, (3 '') optionally substituted C1-6 alkyl (as defined above), (4 '') C6-14 aryl optionally substituted by 1 to 5 substituent (s) selected from the group previous B, (5 '') heterocyclic group optionally substituted by 1 to 5 substituent (s) selected from the previous group B, or (6 '') alkyl heterocycle |
| priorityDate | 2001-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 121.